Determination of the cytotoxic catechol metabolite of etoposide (3′O-demethyletoposide) in human plasma by high-performance liquid chromatography

Stremetzne, S.; Jaehde, Ulrich; Schunack, Walter

doi:10.1016/s0378-4347(97)00410-6

Cited by 19 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This compound has been identified also as a metabolite of ETP in human plasma and urine (Cai et al, 1999) and it exhibits important cytotoxic activity by directly inactivating biologically active DNA (Stremetzne et al, 1997).…”

Section: Identification Of Etp By-productsmentioning

confidence: 99%

Degradation of the cytostatic etoposide in chlorinated water by liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry: Identification and quantification of by-products in real water samples

Negreira

Alda

Barceló

2015

Science of The Total Environment

View full text Add to dashboard Cite

Section: Identification Of Etp By-productsmentioning

confidence: 99%

Degradation of the cytostatic etoposide in chlorinated water by liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry: Identification and quantification of by-products in real water samples

Negreira

Alda

Barceló

2015

Science of The Total Environment

View full text Add to dashboard Cite

“…Etoposide levels in the CSF were assayed by reversed-phase highperformance liquid chromatography (HPLC) using two previously described methods (Farina et al, 1981;Stremetzne et al, 1997). In brief, a Hypersil® ODS RP-18 column (Knauer, Berlin, Germany) was used as the stationary phase.…”

Section: Assay Methodologymentioning

confidence: 99%

Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours

et al. 2001

Self Cite

View full text Add to dashboard Cite

SummaryAs the systemic administration of etoposide is effective in the treatment of relapsed and metastatic brain tumours, a pilot trial was designed to study the feasibility of intraventricular administration of etoposide in such patients. 14 patients aged 2.1 to 33.2 years were treated with intraventricular etoposide simultaneously with either oral or intravenous chemotherapy with trofosfamide or carboplatin and etoposide. In 59 courses (1-12/patient) 0.5 mg etoposide was administered daily via an indwelling subcutaneous reservoir for 5 consecutive days every 2-5 weeks over a period of 0-11 months. During 15 courses in 5 patients serial CSF samples were obtained and etoposide levels were determined by reversed-phase HPLC. Side effects included transient headache and bacterial meningitis, each during 2 courses. Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4±1.2 hours and an AUC of 25.0 ± 9.5 µg h ml -1 (mean ± standard deviation). The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16 l and 0.46 ml min -1 respectively. Intraventricularly administered etoposide is well tolerated. CSF peak levels exceed more than 100-fold those achieved with intravenous infusions. Further studies should be focused on optimizing the dose and schedule and on determining the effectiveness of intraventricularly administered etoposide.

show abstract

“…polyphenols) instead of liposolubility (log P=6.03), as depicted for 4-NRC (Freitas, 1999). Therefore, in response to the need for a sensitive method to quantify 4-NRC, we examined methods using liquid chromatography coupled to electrochemical detection (Cai et al, 1999;Stremetzne, Jaehde, Schumack, 1997;Holmes, Eisenhofer, Goldstein, 1994;Lunte, 1987;El-Shafae, El-Domiaty, 2001) and ultraviolet detection (Romanova et al, 2000;Rouseff et al, 1992;Ruperez et al, 1999;Castagnetta et al, 1992), as primarily options. Such methods generally show suitable sensitivity for plasma samples, even when compared to more selective ones (Lee et al, 1993;Stecher et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Quantification of 4-nerolidylcatechol from Pothomorphe umbellata (Piperaceae) in rat plasma samples by HPLC-UV

Rezende

Barros

2004

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

The oral dosages formulations from Pothomorphe umbellata (Piperaceae) can only be therapeutically evaluated after establishing 4-nerolidylcatechol (4-NRC) pharmacokinetic profile in plasma. For that purpose, a unique analytical method validation using HPLC-UV detection was developed for analysis of rat plasma samples. The animals received 10 mg/kg b.w. of 4-NRC i.v.. Analytical conditions were set with C18 column, methanol: acetonitrile: water (62:20:18) as mobile phase, and a flow rate of 1.6 mL/min. The assay was linear from 1.0-80.0 mcg/mL. The recovery procedure was performed by liquid-liquid extraction showing quantitative extraction (106.4±8.7%). Limit of Quantification (LOQ) was found to be 1.0 mcg/mL. Interassay precision and accuracy ranged from values of 14.4-3.0% and 24.0-0.2%, respectively. Recovery after liquid-liquid extraction was found to be 106.5 ± 3%. The method is simple and reliable with total run time of less than 15 min.

show abstract

Determination of the cytotoxic catechol metabolite of etoposide (3′O-demethyletoposide) in human plasma by high-performance liquid chromatography

Cited by 19 publications

References 12 publications

Degradation of the cytostatic etoposide in chlorinated water by liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry: Identification and quantification of by-products in real water samples

Degradation of the cytostatic etoposide in chlorinated water by liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry: Identification and quantification of by-products in real water samples

Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours

Quantification of 4-nerolidylcatechol from Pothomorphe umbellata (Piperaceae) in rat plasma samples by HPLC-UV

Contact Info

Product

Resources

About